Clinical Trials
Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Depression: The ASPIRIN BD Phase II Trial
Dominiak et alJournal of clinical medicine

In the multicentre, randomised, double-blind, placebo-controlled phase II ASPIRIN BD trial conducted across four centres in Poland, investigators evaluated the efficacy and safety of adjunctive low-dose acetylsalicylic acid (ASA; 150 mg/day) in 100 adults aged 18 to 60 years experiencing a current bipolar depressive episode. Participants were randomised 1:1 to receive either adjunctive ASA (n = 50) or placebo (n = 50) for a total duration of 12 months.
The trial's primary endpoint was the change in 17-item Hamilton Depression Rating Scale (HAMD-17) score after 2 months of treatment, with secondary assessments evaluating relapse or clinical worsening over 12 months. At month 2, adjunctive ASA reduced HAMD-17 scores compared to placebo, showing an adjusted difference of -4.24 (95% CI -7.20 to -1.28; p = 0.005; Cohen's d = -0.51). Over the 12-month follow-up period, relapse or clinical worsening occurred less frequently with ASA than with placebo (p = 0.026; number needed to treat [NNT] = 5). In addition, both depressive and bipolar remission rates were higher in the ASA group at month 6 (both p ≤ 0.003).
Adherence rates and safety outcomes were comparable between the ASA and placebo cohorts, with no clear safety signal observed during the 12-month treatment period. The study authors concluded that adjunctive ASA 150 mg/day improved short-term depressive symptoms and reduced relapse or clinical worsening, noting that these findings warrant phase III trial confirmation.
Key Takeaways
- Adjunctive acetylsalicylic acid 150 mg/day reduced 2-month HAMD-17 scores compared with placebo in adults with bipolar depression (adjusted difference -4.24; 95% CI -7.20 to -1.28; p = 0.005; d = -0.51).
- Over 12 months, relapse or clinical worsening was less frequent in the acetylsalicylic acid group (p = 0.026; NNT = 5), with higher rates of depressive and bipolar remission at month 6 (both p ≤ 0.003) and comparable safety outcomes between groups.
Read the original sourceJournal of clinical medicine
